Nuvectra Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
3,043.00
3,696.00
5,238.00
12,535.00
31,836.00
48,831
Cost of Goods Sold (COGS) incl. D&A
1,355.00
1,910.00
3,527.00
6,589.00
16,046.00
22,997
Gross Income
1,688.00
1,786.00
1,711.00
5,946.00
15,790.00
25,834
SG&A Expense
25,832.00
23,135.00
25,815.00
42,872.00
57,802.00
69,022
EBIT
24,231.00
21,424.00
24,145.00
36,926.00
42,012.00
43,188
Unusual Expense
150.00
20.00
271.00
469.00
604.00
-
Non Operating Income/Expense
-
-
-
278.00
-
390
Interest Expense
-
-
-
1,411.00
2,259.00
4,688
Pretax Income
24,081.00
21,444.00
24,416.00
38,428.00
44,575.00
47,166
Income Tax
-
-
-
-
25.00
21
Consolidated Net Income
24,081.00
21,444.00
24,416.00
38,428.00
44,600.00
47,145
Net Income
24,081.00
21,444.00
24,416.00
38,428.00
44,600.00
47,145
Net Income After Extraordinaries
24,081.00
21,444.00
24,416.00
38,428.00
44,600.00
46,159
Net Income Available to Common
24,081.00
21,444.00
24,416.00
38,428.00
44,600.00
48,131
EPS (Basic)
2.35
2.09
2.38
3.74
4.22
3.25
Basic Shares Outstanding
10,259.60
10,259.60
10,259.60
10,277.00
10,576.00
14,801
EPS (Diluted)
2.35
2.09
2.38
3.74
4.22
3.25
Diluted Shares Outstanding
10,259.60
10,259.60
10,259.60
10,277.00
10,576.00
14,801
EBITDA
23,585.00
20,363.00
23,558.00
34,683.00
40,397.00
41,702
Other Operating Expense
87.00
75.00
41.00
-
-
-
Non-Operating Interest Income
-
-
-
100.00
300.00
1,100

About Nuvectra

View Profile
Address
5830 Granite Parkway
Plano Texas 75024
United States
Employees -
Website http://www.nuvectramed.com
Updated 07/08/2019
Nuvectra Corp. engages in the development and commercialization of neurostimulation technology platform for treatment of various disorders through stimulation of tissues associated with the nervous systems. It operates through Nuvectra, and NeuroNexus segments. The Nuvectra segmeng is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions.